|
|
Post by akemp3000 on Sept 1, 2021 4:24:08 GMT -5
Wondering if others have pondered the possibility there's more riding on this anticipated upcoming FDA approval for UTHR than meets the eye? Martine put up $105 million to expedite this approval to stay well ahead of potential competition. A second indication for the drug’s use was also submitted and approved which means the potential for success is quite large. Additionally, I believe there's another unnamed molecule and indication being investigated by these two companies. Based on this and the fact UTHR has the resources and Mannkind could still use a powerhouse partner, it would not be surprising if there's some form of buy-in, merger or something sitting in the background between UTHR and MNKD dependent on this upcoming approval. UTHR could even simply buyout specific indications which would give them total control and provide Mannkind with needed funds to pursue the many other pipeline applications desired creating a win/win for both companies. Just thinking FDA approval would be required before any such deal would transpire. If so, it would not be surprising to hear such an announcement shortly after the FDA approval. Just thinking out loud that the possibility exists and would certainly be a joy to see...well, unless you're short  |
|
|
|
Post by winner on Sept 1, 2021 7:50:25 GMT -5
Good morning akemp3000. For what it's worth, I agree 100%. I for one am glad you started this thread. I.M.H.O. it doesn't make sense for UTHR to allow MNKD to be able to influence their overall game plan. It would be so much simpler if UTHR bought MNKD and acquired 100% of current and future joint developments.
|
|
|
|
Post by uvula on Sept 1, 2021 8:14:38 GMT -5
Many people here including me have been saying this for months. But I think it could be even bigger now. A major pharma company could acquire mnkd, uthr, rls, and nrxp.
To those that say that MC would never allow this: everyone has a price.
|
|
|
|
Post by dh4mizzou on Sept 1, 2021 8:19:36 GMT -5
Uvula. So I have to ask THE question. What $$$ would you see as fair value for MNKD?
|
|
|
|
Post by nylefty on Sept 1, 2021 8:22:12 GMT -5
Many people here including me have been saying this for months. But I think it could be even bigger now. A major pharma company could acquire mnkd, uthr, rls, and nrxp. To those that say that MC would never allow this: everyone has a price. It would be up to the BOD and a vote by the shareholders. MC doesn't own the company. |
|
|
|
Post by akemp3000 on Sept 1, 2021 8:26:43 GMT -5
UTHR, or any major drug company for that matter, would certainly prefer to have total control of what will probably soon become their primary product(s). The question would be whether or not UTHR would want to be involved with all the other applications in Mannkind's pipeline. They certainly have the horsepower to buy all and either keep or spin off what they wish but IMO, they'd probably rather only want their family of drugs. From Mannkind's perspective, my guess is they would prefer to keep the company and the balance of the pipeline potential as it seems to be on the ground floor with enormous potential.
In this scenario, the question to Mannkind would be whether or not they would prefer to have continued royalties from UTHR for years to come or accept a lower but current cash offer that would give UTHR total control of their drugs and Mannkind the funds to move forward as the development company it's always wanted to become. This would be a win/win and is all about the math and expectations of each moving forward. I'm not counting on what could certainly be a blockbuster announcement immediately following the FDA approval, but the scenario is worth pondering. As Uvula is saying, it's all about the price.
|
|
|
|
Post by akemp3000 on Sept 1, 2021 8:33:27 GMT -5
Many people here including me have been saying this for months. But I think it could be even bigger now. A major pharma company could acquire mnkd, uthr, rls, and nrxp. To those that say that MC would never allow this: everyone has a price. It would be up to the BOD and a vote by the shareholders. MC doesn't own the company. I agree though based on history, the board has controlled the shareholder votes. That might not be true any longer if an attractive offer were to come along. What a fun thing to think about though many of us who have followed this company for years have been burned by speculative thoughts. That said, the current environment sure seems much different and better than the past. |
|
|
|
Post by uvula on Sept 1, 2021 8:42:09 GMT -5
What a great position for all of us armchair quarterbacks to be in. Trying to figure out if we would make more money if mnkd stays independent or if mnkd gets acquired by another company.
|
|
|
|
Post by ryster505 on Sept 1, 2021 9:15:20 GMT -5
I have said for quite some time that large BPs typically like to own the entirety of their drugs, especially given the amount of potential royalties, I wouldn’t be surprised for them to make a move on Trep-T and offer to buy it out. Would be some MAJOR $…
|
|
|
|
Post by longliner on Sept 1, 2021 9:51:58 GMT -5
Martine builds and sells companies. LLY or another major taking the entire pile (UTHR, MNKD, RLS, Nrxp, etc.) at once would not be a stretch given the amount of liquidity in the markets right now, and the cash hoards of BP's.
|
|
|
|
Post by Chris-C on Sept 1, 2021 9:54:00 GMT -5
Wondering if others have pondered the possibility there's more riding on this anticipated upcoming FDA approval for UTHR than meets the eye? Martine put up $105 million to expedite this approval to stay well ahead of potential competition. A second indication for the drug’s use was also submitted and approved which means the potential for success is quite large. Additionally, I believe there's another unnamed molecule and indication being investigated by these two companies. Based on this and the fact UTHR has the resources and Mannkind could still use a powerhouse partner, it would not be surprising if there's some form of buy-in, merger or something sitting in the background between UTHR and MNKD dependent on this upcoming approval. UTHR could even simply buyout specific indications which would give them total control and provide Mannkind with needed funds to pursue the many other pipeline applications desired creating a win/win for both companies. Just thinking FDA approval would be required before any such deal would transpire. If so, it would not be surprising to hear such an announcement shortly after the FDA approval. Just thinking out loud that the possibility exists and would certainly be a joy to see...well, unless you're short Actually, I may be the only long on the board who would not be pleased with a buyout scenario. I've been in this non-productive investment for 12 years, and a buyout by anyone at this juncture would likely NOT be anywhere near what I expect to recoup for my time and money. The share price would need to be well North of $25 per share before I'd be happy. Even at $25 that is a 5x multiple of where it stands now, not considering the reverse split. Not going to happen. Otherwise, a one time payment to buy out the rights to the molecule is not particularly appealing to me either. What would be appropriate? Even if Mannkind got a payment that erased their debt and had 500 million in the bank (also unlikely), the street probably won't change its negative sentiment and send the share price to the moon. The sentiment will change when MNKD has a dependable, regular income stream with another approved product besides Afrezza and Tyvaso DPI that produces positive earnings that are showing growth, i.e., creating balance sheet verifiable shareholder value. In short, I cannot imagine a buy out scenario of any variety that would make it worthwhile for longs who have endured this investment for a decade or longer. FWIW, I doubt that Al Mann would be in favor of it, either. GLTAL Chris C |
|
|
|
Post by liane on Sept 1, 2021 10:28:31 GMT -5
I don't want a sale here either.
|
|
|
|
Post by sugarland on Sept 1, 2021 10:40:07 GMT -5
I agree Chris! But currently, what is the way to achieve this study income stream? Your golden goose, and the one that’s 100% yours, extremely effective when dosed correctly, and has the market potential. This is why I stay in the afrezza base camp. There has to be a way to turn the tide. Show 3 - 6 months of some legit weekly growth and you’ll quickly see stock price appreciation and company value. Expand the pipeline - absolutely, but nows a great time to see a concerted effort to restructuring and market afrezza. Bring together a strategic afrezza plan with numbers and a United approval by years end and things will look a lot different on paper.
|
|
|
|
Post by sr71 on Sept 1, 2021 11:00:57 GMT -5
An all cash buyout would disadvantage those who hold MNKD covered calls since their shares would most likely be called away, negating much of their gains from the larger increase in stock price.
|
|
|
|
Post by radgray68 on Sept 1, 2021 11:17:14 GMT -5
I'd like to see an offer to buy.
Then I'd like to see it declined.
Then, a bidding war for us among the big 3 insulin cartel because we're gaining so much of their market share they have shareholders pounding the table, asking for their heads.
Then, I'd like to hear Al Mann's laughter as he gets a posthumous Nobel prize for his achievements.
Then, I'd like to hear my bank's president tell me they can't handle any more of my money because it's too much. 🤑
In that order.
After all this company and the investors have been through, I think we're owed a little fanfare at some point
|
|
